Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Phase of Trial: Phase III
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Ruxolitinib (Primary) ; Hydroxycarbamide
- Indications Polycythaemia vera
- Focus Registrational; Therapeutic Use
- Acronyms RELIEF
- Sponsors Incyte Corporation
- 01 Aug 2016 Status changed from active, no longer recruiting to completed.
- 05 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
- 02 Nov 2015 Planned End Date changed from 1 Jun 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History